Comment on “Phenobarbital Versus Benzodiazepine‐Based Pathways for Alcohol Withdrawal Syndrome in Critically Ill Adults: A Systematic Review and Meta‐Analysis”
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026-11 · 46 (11)
DOI: 10.1002/phar.70210 ↗Kurz gefasst
Leserbrief in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 22.10.2026. Verfasst von Chih-Ping Lin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Psychiatry, Taoyuan Psychiatric Center, Ministry of Health and Welfare, Taoyuan City, Taiwan (Republic of China). Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of General Psychiatry, Taoyuan Psychiatric Center, Ministry of Health and Welfare, Taoyuan City, Taiwan (Republic of China).
- Department of Addiction Psychiatry, Taoyuan Psychiatric Center, Ministry of Health and Welfare, Taoyuan City, Taiwan (Republic of China).
ORCID-Profile: Lien-Chung Wei
Zitieren
APA
Lin, C. P., & Wei, L. C. (2026). Comment on “Phenobarbital Versus Benzodiazepine‐Based Pathways for Alcohol Withdrawal Syndrome in Critically Ill Adults: A Systematic Review and Meta‐Analysis”. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 46(11). https://doi.org/10.1002/phar.70210
Vancouver
Lin CP, Wei LC. Comment on “Phenobarbital Versus Benzodiazepine‐Based Pathways for Alcohol Withdrawal Syndrome in Critically Ill Adults: A Systematic Review and Meta‐Analysis”. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026;46(11). doi:10.1002/phar.70210
BibTeX
@article{Lin2026,
author = {Lin, Chih-Ping and Wei, Lien-Chung},
title = {Comment on “Phenobarbital Versus Benzodiazepine‐Based Pathways for Alcohol Withdrawal Syndrome in Critically Ill Adults: A Systematic Review and Meta‐Analysis”},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2026},
volume = {46},
number = {11},
doi = {10.1002/phar.70210}
}
EUVIMED